DOCSLIB.ORG

Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com Oncology Comprehensive Drug List krogerspecialtypharmacy.com Breast Cancer Abraxane® (paclitaxel (protein bound)) Ibrance® (palbociclib) Talzenna® (talazoparib) Afinitor® (everolimus) Ixempra® (ixabepilone) Taxol® (paclitaxel) Cytoxan® (cyclophosphamide) Kadcyla® (ado-trastuzumab emtansine) Taxotere® (docetaxel) Faslodex® (fulvestrant) Kisqali® (ribociclib) Tykerb® (lapatinib) Halaven (eribulin mesylate) Perjeta® (pertuzumab) Xeloda® (capecitabine) Herceptin Hylecta™ (trastuzumab/hyaluronidase) Phesgo® (pertuzumab, trastuzumab, and hyaluronidase) Herceptin® (trastuzumab) Piqray® (alpelisib) Blood Modifying Agents Aranesp® (darbepoetin alfa) Jadenu® (deferasirox) Nyvepria™ (pegfilgrastim) Doptelet® (avatrombopag) Leukine® (sargramostim) Procrit® (epoetin alfa) Elitek® (rasburicase) Mozobil (plerixafor) Promacta® (eltrombopag) Epogen® (epoetin alfa) Neulasta® (pegfilgrastim) Retacrit® (epoetin alfa) Exjade® (deferasirox) Neupogen® (filgrastim) Udenyca® (pegfilgrastim) Fulphila® (pegfilgrastim) Nivestym® (filgrastim-aafi) Zarxio® (filgrastim) Granix® (filgrastim) Nplate® (romiplostim) Ziextenzo® (pegfilgrastim) Prostate & Renal Cell Cancer Eligard® (leuprolide) Nilandron® (nilutamide) Xtandi® (enzalutamide) Erleada® (apalutamide) Sutent® (sunitinib) Yonsa® (abiraterone acetate) Firmagon® (degarelix) Torisel® (temsirolimus) Zoladex® (goserelin) Inlyta® (axitinib) Trelstar® (triptorelin pamoate) Zytiga® (abiraterone acetate) Jevtana® (cabazitaxel) Votrient® (pazopanib) Lupron Depot® (leuprolide) Xgeva® (denosumab) Lymphoma & Leukemia Alkeran® (melphalan) Folotyn® (pralatrexate) Revlimid® (lenalidomide) Bendeka® (bendamustine) Gazyva® (obinutuzumab) Rituxan Hycela® (rituximab and hyaluronidase) Besponsa® (inotuzumab ozogamicin) Gleevec® (imatinib) Rituxan® (rituximab) Blincyto® (blinatumomab) Hemady™ (dexamethasone) Rydapt® (midostaurin) Bosulif® (bosutinib) Intron A® (interferon Alfa-2b) Sprycel® (dasatinib) Cytosar-U® (cytarabine) Kyprolis® (carfilzomib) Targretin® (bexarotene) Dacogen® (decitabine) Mylotarg™ (gemtuzumab ozogamicin) Tasigna® (nilotinib) Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Ninlaro® (ixazomib) Thalomid® (thalidomide) Darzalex® (daratumumab) Oncaspar® (pegaspargase) Velcade® (bortezomib) Daurismo™ (glasdegib) Onureg™ (azacitidine) Vidaza® (azacitidine Powder for injection) Empliciti® (elotuzumab) Polivy™ (polatuzumab vedotin) Zolinza® (vorinostat) Farydak (panobinostat) Pomalyst® (pomalidomide) Lung Cancer Alimta® (pemetrexed) Mekinist® (trametinib) Vizimpro® (dacomitinib) Gemzar® (gemcitabine) Tabrecta® (capmatinib) Xalkori® (crizotinib) Hycamtin® (topotecan) Tafinlar® (dabrafenib) Zykadia® (ceritinib) Lorbrena® (lorlatinib) Tarceva® (erlotinib) Melanoma & Basal Cell Carcinoma Braftovi® (encorafenib) Mektovi® (binimetinib) Tafinlar® (dabrafenib) Cotellic® (cobimetinib) Odomzo® (sonidegib) Yervoy® (ipilimumab) Erivedge® (vismodegib) Opdivo® (nivolumab) Zelboraf® (vemurafenib) Mekinist® (trametinib) Sylatron™ (peginterferon Alfa-2b) Other Cancers Adriamycin® (doxorubicin hydrochloride) Leucovorin Calcium Temodar® (temozolomide) Adrucil® (fluorouracil, 5-FU) Mutamycin® (mitomycin) Toposar®/VePesid® (etoposide, VP-16) Avastin® (bevacizumab) Mvasi™ (bevacizumab) Vectibix® (panitumumab) Doxil® (doxorubicin hydrochloride liposomal) Paraplatin® (carboplatin) Yondelis® (trabectedin) Eloxatin® (oxaliplatin) Platinol® (cisplatin) Zaltrap® (ziv-aflibercept (Systemic)) Erbitux® (cetuximab) Somatuline® Depot (lanreotide) Zirabev® (bevacizumab) Keytruda® (pembrolizumab) Tecentriq® (atezolizumab) Zometa® (zoledronic acid) Oncology Comprehensive Drug List krogerspecialtypharmacy.com Kroger Specialty Pharmacy Oncology Drugs Abraxane® (paclitaxel (protein bound)) Hycamtin® (topotecan) Rituxan® (rituximab) Adriamycin® (doxorubicin hydrochloride) Ibrance® (palbociclib) Rydapt® (midostaurin) Adrucil® (fluorouracil, 5-FU) Inlyta® (axitinib) Somatuline® Depot (lanreotide) Afinitor® (everolimus) Intron A® (interferon Alfa-2b) Sprycel® (dasatinib) Alimta® (pemetrexed) Ixempra® (ixabepilone) Sutent® (sunitinib) Alkeran® (melphalan) Jadenu® (deferasirox) Sylatron™ (peginterferon Alfa-2b) Aranesp® (darbepoetin alfa) Jevtana® (cabazitaxel) Tabrecta® (capmatinib) Avastin® (bevacizumab) Kadcyla® (ado-trastuzumab emtansine) Tafinlar® (dabrafenib) Bendeka® (bendamustine) Keytruda® (pembrolizumab) Talzenna® (talazoparib) Besponsa® (inotuzumab ozogamicin) Kisqali® (ribociclib) Tarceva® (erlotinib) Blincyto® (blinatumomab) Kyprolis® (carfilzomib) Targretin® (bexarotene) Bosulif® (bosutinib) Leucovorin Calcium Tasigna® (nilotinib) Braftovi® (encorafenib) Leukine® (sargramostim) Taxol® (paclitaxel) Cotellic® (cobimetinib) Lorbrena® (lorlatinib) Taxotere® (docetaxel) Cytosar-U® (cytarabine) Lupron Depot® (leuprolide) Tecentriq® (atezolizumab) Cytoxan® (cyclophosphamide) Mekinist® (trametinib) Temodar® (temozolomide) Dacogen® (decitabine) Mektovi® (binimetinib) Thalomid® (thalidomide) Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Mozobil (plerixafor) Toposar®/VePesid® (etoposide, VP-16) Darzalex® (daratumumab) Mutamycin® (mitomycin) Torisel® (temsirolimus) Daurismo™ (glasdegib) Mvasi™ (bevacizumab) Trelstar® (triptorelin pamoate) Doptelet® (avatrombopag) Mylotarg™ (gemtuzumab ozogamicin) Tykerb® (lapatinib) Doxil® (doxorubicin hydrochloride liposomal) Neulasta® (pegfilgrastim) Udenyca® (pegfilgrastim) Eligard® (leuprolide) Neupogen® (filgrastim) Vectibix® (panitumumab) Elitek® (rasburicase) Nilandron® (nilutamide) Velcade® (bortezomib) Eloxatin® (oxaliplatin) Ninlaro® (ixazomib) Vidaza® (azacitidine Powder for injection) Empliciti® (elotuzumab) Nivestym® (filgrastim-aafi) Vizimpro® (dacomitinib) Epogen® (epoetin alfa) Nplate® (romiplostim) Votrient® (pazopanib) Erbitux® (cetuximab) Nyvepria™ (pegfilgrastim) Xalkori® (crizotinib) Erivedge® (vismodegib) Odomzo® (sonidegib) Xeloda® (capecitabine) Erleada® (apalutamide) Oncaspar® (pegaspargase) Xgeva® (denosumab) Exjade® (deferasirox) Onureg™ (azacitidine) Xtandi® (enzalutamide) Farydak (panobinostat) Opdivo® (nivolumab) Yervoy® (ipilimumab) Faslodex® (fulvestrant) Paraplatin® (carboplatin) Yondelis® (trabectedin) Firmagon® (degarelix) Perjeta® (pertuzumab) Yonsa® (abiraterone acetate) Folotyn® (pralatrexate) Phesgo® (pertuzumab, trastuzumab, and hyaluronidase) Zaltrap® (ziv-aflibercept (Systemic)) Fulphila® (pegfilgrastim) Piqray® (alpelisib) Zarxio® (filgrastim) Gazyva® (obinutuzumab) Platinol® (cisplatin) Zelboraf® (vemurafenib) Gemzar® (gemcitabine) Polivy™ (polatuzumab vedotin) Ziextenzo® (pegfilgrastim) Gleevec® (imatinib) Pomalyst® (pomalidomide) Zirabev® (bevacizumab) Granix® (filgrastim) Procrit® (epoetin alfa) Zoladex® (goserelin) Halaven (eribulin mesylate) Promacta® (eltrombopag) Zolinza® (vorinostat) Hemady™ (dexamethasone) Retacrit® (epoetin alfa) Zometa® (zoledronic acid) Herceptin Hylecta™ (trastuzumab/hyaluronidase) Revlimid® (lenalidomide) Zykadia® (ceritinib) Herceptin® (trastuzumab) Rituxan Hycela® (rituximab and hyaluronidase) Zytiga® (abiraterone acetate) Get More Information This list reflects available medications at date of publishing. Kroger Specialty Pharmacy is continuously adding new oncology medications as they become available. To review our oncology referral forms, visit krogerspecialtypharmacy.com/prescriber/referral-forms or contact us at 888.506.2962. Date Published: 07/26/21 2970-072621-1246.
Load more

Recommended publications
  • Identification of Recurrent Mutational Events in Anorectal Melanoma
    Modern Pathology (2017) 30, 286–296 286 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 Identification of recurrent mutational events in anorectal melanoma Hui Min Yang1,2,6, Susan J Hsiao1,6, David F Schaeffer2, Chi Lai3, Helen E Remotti1, David Horst4, Mahesh M Mansukhani1 and Basil A Horst1,5 1Department of Pathology & Cell Biology, Columbia University Medical Center, New York, NY, USA; 2Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; 3Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada; 4Pathologisches Institut, Ludwig-Maximilians-Universitaet, Muenchen, Germany and 5Department of Dermatology, Columbia University Medical Center, New York, NY, USA Anorectal melanoma is a rare disease that carries a poor prognosis. To date, limited genetic analyses confirmed KIT mutations as a recurrent genetic event similar to other mucosal melanomas, occurring in up to 30% of anorectal melanomas. Importantly, a subset of tumors harboring activating KIT mutations have been found to respond to c-Kit inhibitor-based therapy, with improved patient survival at advanced tumor stages. We performed comprehensive targeted exon sequencing analysis of 467 cancer-related genes in a larger series of 15 anorectal melanomas, focusing on potentially actionable variants based on gain- and loss-of-function mutations. We report the identification of oncogenic driver events in the majority (93%) of anorectal melanomas. These included variants in canonical MAPK pathway effectors rarely observed in cutaneous melanomas (including an HRAS mutation, as well as a BRAF mutation resulting in duplication of threonine 599), and recurrent mutations in the tumor suppressor NF1 in 20% of cases, which represented the second-most frequently mutated gene after KIT in our series.
    [Show full text]
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Investigator Initiated Study IRB-29839 an Open-Label Pilot Study To
    Investigator Initiated Study IRB-29839 An open-label pilot study to evaluate the efficacy and safety of a combination treatment of Sonidegib and BKM120 for the treatment of advanced basal cell carcinomas Version 05 September 2016 NCT02303041 DATE: 12Dec2018 1 Coordinating Center Stanford Cancer Center 875 Blake Wilbur Drive Stanford, CA 94305 And 450 Broadway, MC 5334 Redwood City, CA 94603 Protocol Director and Principal Investigator Anne Lynn S Chang, MD, Director of Dermatological Clinical Trials 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Co-Investigator Anthony Oro, MD PhD 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Biostatistician Shufeng Li, MS 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Study Coordinator Ann Moffat 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] 2 Table of Contents 1 Background ................................................................. 7 1.1 Disease Background ..................................................... 7 1.2 Hedgehog Pathway and mechanism of action ............................... 7 1.3 PI3K Pathway and mechanism of action ................................... 9 1.4 Sonidegib Compound Information ............ Error! Bookmark not defined. 1.4.1 Preclinical Studies for Sonidegib ....................................................................11 1.4.2 Muscular system...............................................................................................13 1.4.3 Skeletal system ................................................................................................13
    [Show full text]
  • Bosutinib (Bosulif®) (“Boe SUE Ti Nib”)
    Bosutinib (Bosulif®) (“boe SUE ti nib”) How drug is given: By mouth Purpose: To stop the growth of cancer cells in chronic myelogenous leukemia (CML). How to take this drug 1. Take this medication with food. 2. Swallow each tablet whole; do not crush or chew. IF you have trouble swallowing the tablet, the pharmacist will give you specific instructions. 3. IF you miss a dose, take it as soon as possible. However, if it is less than 12 hours until your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double dose. 4. Wash hands after taking the medication. Avoid handling crushed or broken tablets. 5. Do not drink grapefruit juice or eat grapefruit. Also, do not take St. John’s wort. Consuming these may increase the amount of medication in your body and worsen side effects. 6. Bosutinib can interFere with many drugs, which may change how this works in your body. Talk with your doctor before starting any new drugs, including over the counter drugs, natural products, herbals or vitamins. This includes drugs such as Prilosec™. Storage • Store this medication at room temperature 68-77°F (20-25°C), away From heat, moisture, and direct light. Keep this medicine in its original container, out oF reach oF children and pets. Things that may occur during treatment 1. Loose stools or diarrhea may occur within a few days after the drug is started. You may take loperamide (Imodium A-D®) to help control diarrhea. You may buy this at most drug stores.
    [Show full text]
  • PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1
    Self-Administered Oncology Agents Through Preferred Prior Authorization Program Summary FDA APPROVED INDICATIONS3-104 Please reference individual agent product labeling. CLINICAL RATIONALE For the purposes of the Self -Administered Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation, AHFS, or DrugDex with level of evidence of 1 or 2A. SAFETY3-104 Agent(s) Contraindication(s) Afinitor/Afinitor Disperz Hypersensitivity to everolimus, to other rapamycin (everolimus) derivatives None Alecensa (alectinib) Alunbrig (brigatinib) None Ayvakit (avapritinib) None Balversa (erdafitinib) None Hypersensitivity to bosutinib Bosulif (bosutinib) Braftovi (encorafenib) None Brukinsa (zanubrutinib) None Cabometyx None (cabozantinib) Calquence None (acalabrutinib) Caprelsa Congenital long QT syndrome (vandetanib) Cometriq None (cabozantinib) Copiktra (duvelisib) None Cotellic (cobimetinib) None Daurismo (glasdegib) None None Erivedge (vismodegib) Erleada (apalutamide) Pregnancy None Farydak (panobinostat) Fotivda (tivozanib) None Gavreto (pralsetinib) None None Gilotrif (afatinib) Gleevec None (imatinib) Hycamtin Severe hypersensitivity to topotecan (topotecan) None Ibrance (palbociclib) KS_PS_SA_Oncology_PA_ProgSum_AR1020_r0821v2 Page 1 of 19 © Copyright Prime Therapeutics LLC. 08/2021 All Rights Reserved Effective: 10/01/2021 Agent(s) Contraindication(s) None Iclusig (ponatinib) Idhifa (enasidenib) None Imbruvica (ibrutinib)
    [Show full text]
  • Phase I/II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Bevacizumab in Patients with Chemotherapy Refra
    Investigational New Drugs (2019) 37:331–337 https://doi.org/10.1007/s10637-018-0687-5 PHASE II STUDIES Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer Pedro C. Barata1 & Matthew Cooney2 & Prateek Mendiratta 2 & Ruby Gupta3 & Robert Dreicer4 & Jorge A. Garcia3 Received: 25 September 2018 /Accepted: 16 October 2018 /Published online: 7 November 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Summary Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play important roles in prostate cancer progression. Preclinical data in prostate cancer has suggested the potential additive effect dual inhibition of VEGF and mTOR pathways. In this phase I/II trial we assessed the safety and efficacy of bevacizumab in combination with temsirolimus for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Methods In the phase I portion, eligible patients received temsirolimus (20 mg or 25 mg IV weekly) in combination with a fixed dose of IV bevacizumab (10 mg/kg every 2 weeks). The primary endpoint for the phase II portion was objective response measured by either PSA or RECIST criteria. Exploratory endpoints included changes in circulating tumor cells (CTC) and their correlation with PSA response to treatment. Results Twenty-one patients, median age 64 (53–82), with pre- treatment PSA of 205.3 (11.1–1801.0), previously treated with a median of 2 (0–5) lines of therapy for mCRPC received the combination of temsirolimus weekly at 20 mg (n =4)or25mg(n = 17) with bevacizumab 10 mg/kg every 2 weeks (n =21).
    [Show full text]
  • Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus
    ANTICANCER RESEARCH 34: 1939-1946 (2014) Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus SARINA A. PIHA-PAUL1*, SANG JOON SHIN1*, TRIBHAWAN VATS2, NANDITA GUHA-THAKURTA3, JOANN AARON1, MICHAEL RYTTING2, EUGENIE KLEINERMAN2 and RAZELLE KURZROCK4 Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Pediatric Oncology, and 3Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.; 4Moores Cancer Center, The University of California San Diego, La Jolla, CA, U.S.A. Abstract. Background: Pre-clinical findings suggest that Primary central nervous system (CNS) malignancies are the combination treatment with bevacizumab and temsirolimus second most frequent tumors in pediatric patients, with 3.4 could be effective against malignant pediatric central cases per 100,000 person-years of the estimated incidence for nervous system (CNS) tumors. Patients and Methods: Six children and adolescents at or below 19 years of age in the pediatric patients were treated as part of a phase I trial with United States (1, 2). Advances in diagnostic and therapeutic intravenous temsirolimus 25 mg on days 1, 8, 15, and modalities have improved the 5-year survival rates of children bevacizumab at 5, 10, or 15 mg/kg on day 1 of each 21-day with primary CNS tumors (3). However, due to the cycle until disease progression or patient withdrawal. emergence of drug-resistant clones, the outcome is poor in Results: The median patient age was six years (range=3-14 progressive disease. During the past decade, targeted years). The primary diagnoses were glioblastoma multiforme therapies have been increasingly identified for the most (n=2), medullobalstoma (n=2), pontine glioma (n=1) and common adult malignancies.
    [Show full text]
  • Mutant Cancers 2 3 Heinz Hammerlindl1*, Dinoop Ravindran Menon1*, Sabrina Hammerlindl1, Abdullah Al
    Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/1078-0432.CCR-16-2118 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hammerlindl et. al 1 Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS Mutant Cancers 2 3 Heinz Hammerlindl1*, Dinoop Ravindran Menon1*, Sabrina Hammerlindl1, Abdullah Al 4 Emran1, Joachim Torrano1, Katrin Sproesser3, Divya Thakkar1, Min Xiao3, Victoria G. 5 Atkinson5, Brian Gabrielli4, Nikolas K. Haass2, Meenhard Herlyn3, Clemens Krepler3, Helmut 6 Schaider1,2† 7 8 1Dermatology Research Centre, The University of Queensland, The University of 9 Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia; 10 2The University of Queensland, The University of Queensland Diamantina Institute, 11 Translational Research Institute, Brisbane, Australia; 12 3The Wistar Institute, Philadelphia, PA, U.S.A.; 13 4Mater Medical Research Institute, The University of Queensland, Translational Research 14 Institute, Brisbane, Australia; 15 5Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia; 16 *These authors contributed equally to the study 17 18 Running title: 19 Combined aspirin and sorafenib for RAS-mutant cancer therapy 20 21 Key words: 22 Melanoma, Lung Cancer, NRAS, Sorafenib, Aspirin, RAS, ERK, AMPK 23 24 25 26 27 28 1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 1, 2017; DOI: 10.1158/1078-0432.CCR-16-2118 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hammerlindl et. al 1 2 Grant Support 3 This work was funded by the Epiderm Foundation (H.S.), the Princess Alexandra Hospital 4 Research Foundation (PARSS2016_NearMiss) (H.S.), NIH grants PO1 CA114046, P50 5 CA174523, and the Dr.
    [Show full text]
  • SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M
    SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab)
    [Show full text]
  • I4X-JE-JFCM an Open-Label, Multicenter, Phase 1B/2 Study To
    Protocol (e) I4X-JE-JFCM An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) NCT01763788 Approval Date: 12-Jun-2016 I4X-JE-JFCM(e) Clinical Protocol Page 1 1. Protocol I4X-JE-JFCM(e) An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) Confidential Information The information contained in this protocol is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of Necitumumab (IMC-11F8; LY3012211), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Necitumumab (IMC-11F8; LY3012211) Gemcitabine (LY188011) This is a Phase 1b/2 study in the first-line treatment of patients with advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
    [Show full text]
  • Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
    Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 RESEARCH ARTICLE Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers Timothy A. Yap1,2, Rebecca Kristeleit3, Vasiliki Michalarea1, Stephen J. Pettitt4,5, Joline S.J. Lim1, Suzanne Carreira2, Desamparados Roda1,2, Rowan Miller3, Ruth Riisnaes2, Susana Miranda2, Ines Figueiredo2, Daniel Nava Rodrigues2, Sarah Ward1,2, Ruth Matthews1,2, Mona Parmar1,2, Alison Turner1,2, Nina Tunariu1, Neha Chopra1,4, Heidrun Gevensleben2, Nicholas C. Turner1,4, Ruth Ruddle2, Florence I. Raynaud2, Shaun Decordova2, Karen E. Swales2, Laura Finneran2, Emma Hall2, Paul Rugman6, Justin P.O. Lindemann6, Andrew Foxley6, Christopher J. Lord4,5, Udai Banerji1,2, Ruth Plummer7, Bristi Basu8, Juanita S. Lopez1,2, Yvette Drew7, and Johann S. de Bono1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst June 12, 2020; DOI: 10.1158/2159-8290.CD-20-0163 ABSTRACT Preclinical studies have demonstrated synergy between PARP and PI3K/AKT path- way inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient andBRCA1/2 -proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibi- tor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage response (DDR) or PI3K–AKT pathway alterations. The combination was well tolerated. Recommended phase II doses for the two schedules were: olaparib 300 mg twice a day with either capivasertib 400 mg twice a day 4 days on, 3 days off, or capivasertib 640 mg twice a day 2 days on, 5 days off.
    [Show full text]
  • FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
    Wu et al. Journal of Hematology & Oncology (2018) 11:133 https://doi.org/10.1186/s13045-018-0675-4 REVIEW Open Access FLT3 inhibitors in acute myeloid leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2* Abstract FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. Keywords: FMS-like tyrosine kinase 3 inhibitors, Acute myeloid leukemia, Midostaurin, FLT3 Introduction RAS, MEK, and PI3K/AKT pathways [10], and ultim- Acute myeloid leukemia (AML) remains a highly resist- ately causes suppression of apoptosis and differentiation ant disease to conventional chemotherapy, with a me- of leukemic cells, including dysregulation of leukemic dian survival of only 4 months for relapsed and/or cell proliferation [11]. refractory disease [1]. Molecular profiling by PCR and Multiple FLT3 inhibitors are in clinical trials for treat- next-generation sequencing has revealed a variety of re- ing patients with FLT3/ITD-mutated AML. In this re- current gene mutations [2–4]. New agents are rapidly view, we summarized the preclinical and clinical studies emerging as targeted therapy for high-risk AML [5, 6]. on new FLT3 inhibitors, including sorafenib, lestaurtinib, In 1996, FMS-like tyrosine kinase 3/internal tandem du- sunitinib, tandutinib, quizartinib, midostaurin, gilteriti- plication (FLT3/ITD) was first recognized as a frequently nib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG mutated gene in AML [7].
    [Show full text]